Nexentis Technologies Inc. (NXTS) is an Agricultural Chemicals company listed on NASDAQ. In the last 30 days Quantisnow tracked 17 wire items for NXTS, including 9 insider trades, 5 SEC filings and 3 press releases and news items. The most recent was published Nov 10, 2026.
Financial highlights
Full financials- Net income, TTM
- -$16.04M
- Cash
- $7.62M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks41+183%
2026-05-172026-11-08
Mix2490d
- Insider9(38%)
- SEC Filings8(33%)
- Other6(25%)
- Leadership1(4%)
Activity · 52 weeks5442 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECNexentis Technologies Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form PRE 14A filed by Nexentis Technologies Inc.PRE 14A - Nexentis Technologies Inc. (0001789192) (Filer)
- SECNexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- PRNexentis Announces Reverse Stock SplitNess Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, announced that its Board of Directors has approved a one-for-five (1-for-5) reverse stock split of its common stock that is scheduled to become effective for Nasdaq purposes on November 9, 2026. Beginning on November 9, 2026, the Company’s common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 80512Q709. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol "NXTS
- PRNexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with BoltzMitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation Ness Ziona, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company") recently announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC ("Boltz"), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and war
- PRNexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening StageMitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company") today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC ("Boltz"), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warran
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- SECSEC Form PRE 14A filed by Nexentis Technologies Inc.PRE 14A - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form 8-K filed by Nexentis Technologies Inc.8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 4 filed by Nexentis Technologies Inc.4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- PRNexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway AnalysisMitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities Ness Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), today announced that MitoCareX Bio Ltd. ("MitoCareX"), its wholly owned subsidiary, is broadening its existing bioinformatics capabilities to include a greater focus on the analysis of disease-relevant biological pathways within its computational drug-discovery platform. As part of this initiative, MitoCareX has added an expert bioinformatician to its scientific team. Preliminary analyses generated by the Company are
- PRNexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google CloudDeployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. ("Nexentis"), (NASDAQ:NXTS) ("Nexentis" or the "Company"), today announced that MitoCareX Bio Ltd. ("MitoCareX"), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastructure on Google Cloud Platform ("GCP"). The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure deployment
- SECSEC Form 8-K filed by Nexentis Technologies Inc.8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form PRE 14A filed by Nexentis Technologies Inc.PRE 14A - Nexentis Technologies Inc. (0001789192) (Filer)
- PRNexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory BoardLeading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. ("Nexentis"), (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that Prof. Dan T. Major has joined the Scientific Advisory Board ("SAB") of its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"). Prof. Major will provide scientific advice to MitoCareX on the evaluation and application of computational chemistry, and in silico approaches relevant to drug- discover
- PRNexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug DiscoveryEvaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. , (NASDAQ:NXTS) ("Nexentis" or the "Company"), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities. MitoCareX is evaluating established, commercially available approaches for obtaining proteins as part of its
- SECNexentis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form 10-Q filed by Nexentis Technologies Inc.10-Q - Nexentis Technologies Inc. (0001789192) (Filer)
NXTS FAQ
7 questionsWhat is the latest news on NXTS?
In the last 30 days Quantisnow tracked 17 wire items for NXTS: 9 insider trades, 5 SEC filings and 3 press releases and news items. The most recent was published on November 10, 2026.Is NXTS profitable?
No. Nexentis Technologies Inc. reported a net loss of $16.04M for the twelve months ended Jun 30, 2026.How much cash and debt does NXTS have?
Nexentis Technologies Inc. reported $7.62M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NXTS stock trade?
Nexentis Technologies Inc. (NXTS) is listed on NASDAQ.What sector and industry is NXTS in?
Nexentis Technologies Inc. operates in the Industrials sector, Agricultural Chemicals industry.What companies are similar to NXTS?
Notable peers in the same industry include CBUS (Cibus Inc.), MOS (Mosaic Company), ICL (ICL Group Ltd.), AVD (American Vanguard Corporation), CF (CF Industries Holdings Inc.). Compare NXTS side-by-side with any of them on Quantisnow.How can I track NXTS on Quantisnow?
Quantisnow aggregates Nexentis Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTS to receive live email and push alerts on every new disclosure.